# Muscarinic Receptor Antagonists as a Therapy for Diabetic Neuropathy

> **NCT03050827** · PHASE3 · COMPLETED · sponsor: **Eastern Virginia Medical School** · enrollment: 51 (actual)

## Conditions studied

- Diabetic; Neuropathic, Polyneuropathy (Manifestation)

## Interventions

- **DRUG:** 3% oxybutynin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03050827
- **Lead sponsor:** Eastern Virginia Medical School
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05-01
- **Primary completion:** 2017-08-17
- **Final completion:** 2017-12-31
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2019-02-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03050827

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03050827, "Muscarinic Receptor Antagonists as a Therapy for Diabetic Neuropathy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03050827. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*